5.29
-0.445(-7.76%)
Currency In USD
| Previous Close | 5.74 |
| Open | 5.56 |
| Day High | 5.58 |
| Day Low | 5.12 |
| 52-Week High | 46.8 |
| 52-Week Low | 3.76 |
| Volume | 162,500 |
| Average Volume | 163,615 |
| Market Cap | 32.35M |
| PE | -0.3 |
| EPS | -17.47 |
| Moving Average 50 Days | 6.15 |
| Moving Average 200 Days | 16 |
| Change | -0.45 |
If you invested $1000 in Aligos Therapeutics, Inc. (ALGS) since IPO date, it would be worth $14.25 as of June 01, 2025 at a share price of $5.29. Whereas If you bought $1000 worth of Aligos Therapeutics, Inc. (ALGS) shares 3 years ago, it would be worth $173.44 as of June 01, 2025 at a share price of $5.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, to
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
GlobeNewswire Inc.
May 20, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, to
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
GlobeNewswire Inc.
May 08, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, t